Unlike the dopamine-receptor agonists acting sensitively on prolactinomas, or somatostatin analogs acting on growth hormone-secreting adenomas, pharmacologic options for ACTH-secreting adenomas are limited to drugs targeting pituitary tumors, adrenal glands, or peripheral glucocorticoid receptors. Here, GH1 is linked to pituitary tumor.